Caribou Biosciences generated $3941000 in licensing and collaboration revenue in the fourth quarter of 2025 while reporting a net loss of $26488000. Operating expenses declined year over year as research and development and general administrative spending decreased following workforce reductions and pipeline prioritization.

Caribou Biosciences, Inc. reported a net loss of $39.991 million for Q1 2025, an improvement from the $41.234 million net loss in Q1 2024. Total operating expenses decreased to $45.266 million from $48.431 million in the prior year. Total assets as of March 31, 2025, were $273.656 million, down from $313.313 million at the end of 2024.

Caribou Biosciences reported a net loss of $35.5 million for Q4 2024, compared to a net loss of $34.5 million in Q4 2023. Total operating expenses were $41.0 million, with cash, cash equivalents, and marketable securities at $249.4 million as of December 31, 2024.

Caribou Biosciences reported a net loss of $34.7 million for the third quarter of 2024, with licensing and collaboration revenue of $2.0 million. The company's cash, cash equivalents, and marketable securities totaled $281.0 million as of September 30, 2024, expected to fund operations into H2 2026.

Caribou Biosciences reported $311.8 million in cash, cash equivalents, and marketable securities as of June 30, 2024, sufficient to fund its current operating plan into H2 2026. The company's licensing and collaboration revenue was $3.5 million for the quarter, and it experienced a net loss of $37.7 million.

Caribou Biosciences reported a net loss of $41.2 million for the first quarter of 2024, with $345.9 million in cash, cash equivalents, and marketable securities as of March 31, 2024. The company is advancing four clinical-stage programs and expects its current cash to fund operations into Q1 2026.

Caribou Biosciences reported $3.6 million in licensing and collaboration revenue and a net loss of $34.5 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $372.4 million as of December 31, 2023, expected to fund operations into Q1 2026.

Caribou Biosciences reported Q3 2023 financial results, highlighting advancements in their pipeline programs, including CB-010, CB-011, and CB-012. The company's cash, cash equivalents, and marketable securities totaled $396.7 million, expected to fund operations into Q4 2025.

Caribou Biosciences reported a net loss of $29.5 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $292.5 million as of June 30, 2023, which includes a $25.0 million investment from Pfizer. They anticipate funding the current operating plan into Q4 2025.

Caribou Biosciences reported a net loss of $28.0 million for the first quarter of 2023, with $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023. The company is advancing its pipeline of allogeneic CAR-T cell therapies, including the ongoing ANTLER trial for CB-010 and the initiation of patient dosing in the CaMMouflage trial for CB-011.

Caribou Biosciences reported financial results for the fourth quarter and full year 2022 and reviewed recent pipeline progress. The company had $317.0 million in cash, cash equivalents, and marketable securities as of December 31, 2022, and expects these funds to be sufficient to fund its current operating plan into 2025.

Caribou Biosciences reported promising results from its lead allogeneic cell therapy, CB-010, in the ANTLER clinical trial and submitted an IND application for CB-011. The company's financial position remains strong with $342.6 million in cash, cash equivalents, and marketable securities.

Caribou Biosciences reported financial results for the second quarter of 2022, highlighting a strong financial position with $366.1 million in cash, cash equivalents, and marketable securities. The company made significant progress in advancing its pipeline of genome-edited allogeneic CAR-T and CAR-NK cell therapies, including encouraging initial clinical data from the Phase 1 ANTLER trial for CB-010.

Caribou Biosciences reported a net loss of $19.1 million for the first quarter of 2022, compared to a net loss of $13.2 million for the same period in 2021. The company's cash, cash equivalents, and marketable securities totaled $390.8 million as of March 31, 2022.

Caribou Biosciences reported $413.5 million in cash, cash equivalents, and marketable securities as of December 31, 2021. Revenue from licensing and collaboration agreements was $2.6 million for the quarter. Research and development expenses were $15.1 million, and general and administrative expenses were $7.9 million. The net loss for the quarter was $18.5 million.

Caribou Biosciences reported a net loss of $21.0 million for the third quarter of 2021. The company ended the quarter with $435.3 million in cash and cash equivalents, including $321.0 million in net proceeds from its IPO.

Caribou Biosciences reported a net loss of $14.3 million for the second quarter of 2021. The company completed an upsized IPO raising $349.6 million in gross proceeds and dosed the first patient in Phase 1 clinical trial of CB-010.